Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global health context for the military in Defence Engagement (Health).

BMJ military health·2023
Same author

Permanent Vegetative State: Addendum to a Review by a Working Group Convened by the Royal College of Physicians and Endorsed by the Conference of Medical Royal Colleges.

Journal of the Royal College of Physicians of London·2019
Same author

Primary blast lung injury simulator: a new computerised model.

Journal of the Royal Army Medical Corps·2018
Same author

Current issues in neurology.

European journal of neurology·2013
Same author

A guide to facilitate the early treatment of patients with idiopathic demyelinating disease (multiple sclerosis and neuromyelitis optica).

Multiple sclerosis (Houndmills, Basingstoke, England)·2013
Same author

What Affects Clinicians' Usage of Health Information Exchange?

Applied clinical informatics·2011
Same journal

American academy of neurology annual meeting.

International MS journal·2011
Same journal

Tumour Necrosis Factor Neutralization in MS: A Cautionary Tale.

International MS journal·2011
Same journal

The clinical usefulness of routine MRI assessment.

International MS journal·2011
Same journal

Acute Psychosis as the Initial Presentation of MS: A Case Report.

International MS journal·2011
Same journal

Russell Brains Review of MS.

International MS journal·2011
Same journal

Epstein-Barr Virus and MS:Causality or Association?

International MS journal·2011
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Alemtuzumab.

D Bates

    International MS Journal
    |November 11, 2009
    PubMed
    Summary
    This summary is machine-generated.

    Alemtuzumab, a humanized monoclonal antibody, showed significant promise in treating multiple sclerosis (MS) by surpassing existing therapies and reducing disability accumulation. Further research provides a realistic account of its clinical application and history.

    More Related Videos

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
    09:34

    Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

    Published on: February 17, 2022

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
    09:44

    Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

    Published on: January 29, 2019

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
    08:46

    A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

    Published on: November 12, 2019

    Area of Science:

    • Immunology
    • Neurology
    • Clinical Medicine

    Background:

    • The CAMMS 2008 trial reported alemtuzumab (Campath-1H) efficacy for multiple sclerosis (MS).
    • Alemtuzumab demonstrated superior effectiveness compared to standard MS treatments.
    • The therapy involves infusions, potentially less frequent than annual intervals, and appears to slow disability progression.

    Discussion:

    • The lay press sensationalized alemtuzumab as a 'cure' for MS.
    • This paper offers a more balanced perspective on alemtuzumab's role in MS management.
    • It details the Cambridge experience with alemtuzumab and its historical development.

    Key Insights:

    • Alemtuzumab is a long-established humanized monoclonal antibody.
    • Its development journey spans from laboratory origins to clinical application.
    • The drug's potential in managing MS is explored realistically.

    Outlook:

    • Alemtuzumab is progressing towards licensing for clinical use in MS.
    • Ongoing research aims to provide a comprehensive understanding of its long-term benefits and risks.
    • Future strategies will focus on optimizing alemtuzumab's integration into MS treatment protocols.